LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 171

Search options

  1. Article ; Online: Combining next-generation hormonal therapy with PARP inhibition in metastatic castration-resistant prostate cancer.

    Abida, Wassim / Attard, Gerhardt

    Lancet (London, England)

    2023  Volume 402, Issue 10398, Page(s) 266–267

    MeSH term(s) Male ; Humans ; Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Docetaxel/therapeutic use
    Chemical Substances Poly(ADP-ribose) Polymerase Inhibitors ; Docetaxel (15H5577CQD)
    Language English
    Publishing date 2023-06-04
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Comment
    ZDB-ID 3306-6
    ISSN 1474-547X ; 0023-7507 ; 0140-6736
    ISSN (online) 1474-547X
    ISSN 0023-7507 ; 0140-6736
    DOI 10.1016/S0140-6736(23)01123-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.5: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 94: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Accidentals of the DNA Symphony.

    Wu, Anjui / Attard, Gerhardt

    Cancer research

    2022  Volume 82, Issue 21, Page(s) 3880–3881

    Abstract: Cancer epigenome profiling such as DNA methylation (5mC) and DNA hydroxymethylation (5hmC) is emerging as a sensitive approach for cancer detection and risk stratification. 5mC modification has been widely described in many cancer types including ... ...

    Abstract Cancer epigenome profiling such as DNA methylation (5mC) and DNA hydroxymethylation (5hmC) is emerging as a sensitive approach for cancer detection and risk stratification. 5mC modification has been widely described in many cancer types including prostate cancer; however, the 5hmC landscape is yet to be explored. In this issue of Cancer Research, Sjöström and colleagues have comprehensively incorporated genomic, transcriptomic, and epigenomic, including 5hmC, data to interrogate the molecular evolution of prostate cancer. See related article by Sjöström et al., p. 3888.
    MeSH term(s) Humans ; Male ; Prostatic Neoplasms ; DNA ; DNA Methylation
    Chemical Substances 5-hydroxymethylcytosine (1123-95-1) ; DNA (9007-49-2)
    Language English
    Publishing date 2022-11-01
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 1432-1
    ISSN 1538-7445 ; 0008-5472
    ISSN (online) 1538-7445
    ISSN 0008-5472
    DOI 10.1158/0008-5472.CAN-22-2750
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.135/5: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges.

    Trujillo, Blanca / Wu, Anjui / Wetterskog, Daniel / Attard, Gerhardt

    British journal of cancer

    2022  Volume 127, Issue 8, Page(s) 1394–1402

    Abstract: Liquid biopsy has been established as a powerful, minimally invasive, tool to detect clinically actionable aberrations across numerous cancer types in real-time. With the development of new therapeutic agents in prostate cancer (PC) including DNA repair ... ...

    Abstract Liquid biopsy has been established as a powerful, minimally invasive, tool to detect clinically actionable aberrations across numerous cancer types in real-time. With the development of new therapeutic agents in prostate cancer (PC) including DNA repair targeted therapies, this is especially attractive. However, there is unclarity on how best to screen for PC, improve risk stratification and ultimately how to treat advanced disease. Therefore, there is an urgent need to develop better biomarkers to help guide oncologists' decisions in these settings. Circulating tumour cells (CTCs), exosomes and cell-free DNA/RNA (cfDNA/cfRNA) analysis, including epigenetic features such as methylation, have all shown potential in prognostication, treatment response assessment and detection of emerging mechanisms of resistance. However, there are still challenges to overcome prior to implementing liquid biopsies in routine clinical practice such as preanalytical considerations including blood collection and storage, the cost of CTC isolation and enrichment, low-circulating tumour content as a limitation for genomic analysis and how to better interpret the sequencing data generated. In this review, we describe an overview of the up-to-date clinical opportunities in the management of PC through blood-based liquid biopsies and the next steps for its implementation in personalised treatment guidance.
    MeSH term(s) Biomarkers, Tumor/genetics ; Cell-Free Nucleic Acids ; Humans ; Liquid Biopsy ; Male ; Neoplastic Cells, Circulating/pathology ; Prostatic Neoplasms/diagnosis ; Prostatic Neoplasms/genetics ; Prostatic Neoplasms/pathology ; RNA
    Chemical Substances Biomarkers, Tumor ; Cell-Free Nucleic Acids ; RNA (63231-63-0)
    Language English
    Publishing date 2022-06-17
    Publishing country England
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 80075-2
    ISSN 1532-1827 ; 0007-0920
    ISSN (online) 1532-1827
    ISSN 0007-0920
    DOI 10.1038/s41416-022-01881-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.142: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Anti-androgen monotherapy for metastatic prostate cancer.

    Attard, Gerhardt

    The Lancet. Oncology

    2014  Volume 15, Issue 6, Page(s) 543–544

    MeSH term(s) Adenocarcinoma/drug therapy ; Antineoplastic Agents/therapeutic use ; Benzamides ; Humans ; Male ; Nitriles ; Phenylthiohydantoin/analogs & derivatives ; Phenylthiohydantoin/therapeutic use ; Prostatic Neoplasms/drug therapy
    Chemical Substances Antineoplastic Agents ; Benzamides ; Nitriles ; Phenylthiohydantoin (2010-15-3) ; enzalutamide (93T0T9GKNU)
    Language English
    Publishing date 2014-04-14
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 2049730-1
    ISSN 1474-5488 ; 1470-2045
    ISSN (online) 1474-5488
    ISSN 1470-2045
    DOI 10.1016/S1470-2045(14)70159-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5696: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 460: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Plasma DNA Analysis in Prostate Cancer: Opportunities for Improving Clinical Management.

    Wu, Anjui / Attard, Gerhardt

    Clinical chemistry

    2018  Volume 65, Issue 1, Page(s) 100–107

    Abstract: Background: Molecular characterization of tumors could be important for clinical management. Plasma DNA obtained noninvasively as a liquid biopsy could be widely applicable for clinical implementation in biomarker-based treatment strategies.: Content!# ...

    Abstract Background: Molecular characterization of tumors could be important for clinical management. Plasma DNA obtained noninvasively as a liquid biopsy could be widely applicable for clinical implementation in biomarker-based treatment strategies.
    Content: Prostate cancer is a disease with variable clinical outcomes and molecular features and therefore presents multiple opportunities for biomarker-based treatment optimization. Tissue analysis may not be representative of the lethal clone in localized disease or of intrapatient, intermetastases heterogeneity; fresh tissue is often challenging to obtain by biopsy of metastasis, whereas archival samples may not represent current disease and may be of insufficient quality. Plasma DNA is of variable tumor-to-normal fraction that requires accurate estimation using sensitively measured genomic events. In plasma with sufficient tumor content, the spectrum of genomic aberrations closely resembles tissue and could be used to molecularly characterize patients in real time. In this review we discuss the opportunities for improving clinical management by using plasma DNA analysis in different clinical scenarios across the disease spectrum, from detection of prostate cancer and disease relapse to treatment response prediction, response assessment, and interrogation of treatment resistance in metastatic prostate cancer. Combinational strategies may incorporate other modalities, including circulating tumor cells, circulating microRNA, and extracellular vesicles analysis, which could help to achieve more accurate characterization.
    Summary: There are many opportunities for plasma DNA analyses to change clinical management. However, there are challenges that need to be addressed to clinically implement a test, including the development of accurate, fit for purpose, and technically reproducible assay, followed by prospective validation in a large cohort of patients.
    MeSH term(s) Humans ; Liquid Biopsy ; Male ; Neoplasm Metastasis ; Neoplasm, Residual ; Neoplastic Cells, Circulating/metabolism ; Prostatic Neoplasms/blood ; Prostatic Neoplasms/genetics ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms/therapy ; Recurrence ; Translational Research, Biomedical
    Language English
    Publishing date 2018-12-11
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 80102-1
    ISSN 1530-8561 ; 0009-9147
    ISSN (online) 1530-8561
    ISSN 0009-9147
    DOI 10.1373/clinchem.2018.287250
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ud II Zs.171: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Should Patients with High-risk Localised or Locally Advanced Prostate Cancer Receive Abiraterone Acetate in Addition to Androgen Deprivation Therapy? Update on a Planned Analysis of the STAMPEDE Trial.

    Attard, Gerhardt / Brown, Louise C / Clarke, Noel W / Parmar, Mahesh K B / James, Nicholas D

    European urology

    2021  Volume 80, Issue 4, Page(s) 522–523

    MeSH term(s) Abiraterone Acetate ; Androgen Antagonists/adverse effects ; Androgens ; Humans ; Male ; Prednisone ; Prostatic Neoplasms, Castration-Resistant/drug therapy
    Chemical Substances Androgen Antagonists ; Androgens ; Abiraterone Acetate (EM5OCB9YJ6) ; Prednisone (VB0R961HZT)
    Language English
    Publishing date 2021-07-14
    Publishing country Switzerland
    Document type Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 193790-x
    ISSN 1873-7560 ; 1421-993X ; 0302-2838
    ISSN (online) 1873-7560 ; 1421-993X
    ISSN 0302-2838
    DOI 10.1016/j.eururo.2021.06.023
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1247: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 294: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Prostate cancer: AR aberrations and resistance to abiraterone or enzalutamide.

    Attard, Gerhardt / Antonarakis, Emmanuel S

    Nature reviews. Urology

    2016  Volume 13, Issue 12, Page(s) 697–698

    MeSH term(s) Androstenes/pharmacology ; Androstenes/therapeutic use ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Drug Resistance, Neoplasm/drug effects ; Drug Resistance, Neoplasm/genetics ; Humans ; Male ; Phenylthiohydantoin/analogs & derivatives ; Phenylthiohydantoin/pharmacology ; Phenylthiohydantoin/therapeutic use ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms/genetics ; Prostatic Neoplasms/metabolism ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Prostatic Neoplasms, Castration-Resistant/genetics ; Prostatic Neoplasms, Castration-Resistant/metabolism ; Receptors, Androgen/genetics ; Receptors, Androgen/metabolism
    Chemical Substances Androstenes ; Antineoplastic Agents ; Receptors, Androgen ; Phenylthiohydantoin (2010-15-3) ; enzalutamide (93T0T9GKNU) ; abiraterone (G819A456D0)
    Language English
    Publishing date 2016-11-02
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2493737-X
    ISSN 1759-4820 ; 1759-4812
    ISSN (online) 1759-4820
    ISSN 1759-4812
    DOI 10.1038/nrurol.2016.212
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6030: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Plasma DNA and Metastatic Castration-Resistant Prostate Cancer: The Odyssey to a Clinical Biomarker Test.

    Jayaram, Anuradha / Wetterskog, Daniel / Attard, Gerhardt

    Cancer discovery

    2018  Volume 8, Issue 4, Page(s) 392–394

    Abstract: ... Comprehensive plasma DNA analysis identifies clinically actionable genomic aberrations. Cancers harboring disruption ... ...

    Abstract <b/> Comprehensive plasma DNA analysis identifies clinically actionable genomic aberrations. Cancers harboring disruption of
    MeSH term(s) Androstenes ; Benzamides ; Circulating Tumor DNA ; DNA ; Genomics ; Humans ; Male ; Nitriles ; Phenylthiohydantoin/analogs & derivatives ; Prostatic Neoplasms, Castration-Resistant/blood
    Chemical Substances Androstenes ; Benzamides ; Circulating Tumor DNA ; Nitriles ; Phenylthiohydantoin (2010-15-3) ; DNA (9007-49-2) ; enzalutamide (93T0T9GKNU) ; abiraterone (G819A456D0)
    Language English
    Publishing date 2018-04-02
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 2625242-9
    ISSN 2159-8290 ; 2159-8274
    ISSN (online) 2159-8290
    ISSN 2159-8274
    DOI 10.1158/2159-8290.CD-18-0124
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6916: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Circulating Androgen Receptor for Prognosis and Treatment Selection in Prostate Cancer.

    Conteduca, Vincenza / Wetterskog, Daniel / Gonzalez-Billalabeitia, Enrique / Brighi, Nicole / De Giorgi, Ugo / Attard, Gerhardt

    European urology oncology

    2021  Volume 4, Issue 5, Page(s) 740–744

    Abstract: Analysis of androgen receptor (AR) status, particularly AR copy number, in plasma DNA is a minimally invasive method with the potential to identify treatment resistance in patients with castration-resistant prostate cancer (CRPC) starting enzalutamide or ...

    Abstract Analysis of androgen receptor (AR) status, particularly AR copy number, in plasma DNA is a minimally invasive method with the potential to identify treatment resistance in patients with castration-resistant prostate cancer (CRPC) starting enzalutamide or abiraterone. Patients with elevated plasma AR do not have worse outcomes than patients with normal plasma AR when treated with taxanes. Consequently, circulating AR may improve clinical decision-making between AR-directed therapies versus taxanes and probably also between adapted versus standard taxane regimens. The evidence indicates that circulating AR could have a role in overall CRPC management. Promising clinical implications of plasma AR testing are measurement in earlier stages of prostate cancer, disease monitoring, and within the context of a multiplex biomarker strategy to improve treatment selection for CRPC patients. PATIENT SUMMARY: Measurement of the copy number of androgen receptor genes in plasma is a promising tool for guiding personalised treatment in patients with castration-resistant prostate cancer. However, prospective trials to validate these findings are needed.
    MeSH term(s) Humans ; Male ; Patient Selection ; Prognosis ; Prostatic Neoplasms, Castration-Resistant/diagnosis ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Prostatic Neoplasms, Castration-Resistant/genetics ; Receptors, Androgen/genetics
    Chemical Substances AR protein, human ; Receptors, Androgen
    Language English
    Publishing date 2021-01-09
    Publishing country Netherlands
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ISSN 2588-9311
    ISSN (online) 2588-9311
    DOI 10.1016/j.euo.2020.12.009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  10. Article ; Online: Circulating Tumour DNA in Muscle-Invasive Bladder Cancer.

    Tan, Melissa P / Attard, Gerhardt / Huddart, Robert A

    International journal of molecular sciences

    2018  Volume 19, Issue 9

    Abstract: Circulating tumour DNA (ctDNA) is an attractive tool in cancer research, offering many advantages over tissue samples obtained using traditional biopsy methods. There has been increasing interest in its application to muscle-invasive bladder cancer (MIBC) ...

    Abstract Circulating tumour DNA (ctDNA) is an attractive tool in cancer research, offering many advantages over tissue samples obtained using traditional biopsy methods. There has been increasing interest in its application to muscle-invasive bladder cancer (MIBC), which is recognised to be a heterogeneous disease with overall poor prognosis. Using a range of platforms, studies have shown that ctDNA is detectable in MIBC and may be a useful biomarker in monitoring disease status and guiding treatment decisions in MIBC patients. Currently, with no such predictive or prognostic biomarkers in clinical practice to guide treatment strategy, there is a real unmet need for a personalised medicine approach in MIBC, and ctDNA offers an exciting avenue through which to pursue this goal. In this article, we present an overview of work to date on ctDNA in MIBC, and discuss the inherent challenges present as well as the potential future clinical applications.
    MeSH term(s) Animals ; Biomarkers, Tumor/genetics ; Circulating Tumor DNA/genetics ; Humans ; Urinary Bladder Neoplasms/genetics
    Chemical Substances Biomarkers, Tumor ; Circulating Tumor DNA
    Language English
    Publishing date 2018-08-29
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms19092568
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top